Live feed15:30:00·24dPRReleaseAcoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54BBIO· BridgeBio Pharma Inc.Health CareOriginal source
